The treatment of idiopathic thrombocytopenia with vinblastine-loaded platelets.
We devised a method to enhance delivery of vinblastine to macrophages, the cells believed to be responsible for platelet destruction in idiopathic thrombocytopenic purpura. Our strategy was based on the ability of platelets to bind vinca alkaloids such as vinblastine. Platelets were incubated with an excess of vinblastine, concentrated and then, after excess alkaloid had been removed, given to 11 patients with idiopathic thrombocytopenia refractory to other treatment (including intravenous injections of vinca alkaloids). Platelet antibodies in the patients' plasma led to ingestion of the vinca-laden platelets by macrophages. There were six complete remissions, three partial remissions and two failures. Side effects in a few patients, reversible but annoying, were minimized as technics were refined. We conclude that in patients with idiopathic thrombocytopenia refractory to all other measures, including the use of vinca alkaloids, platelet-vinca complex may be effective.
D000293:Adolescent; D000368:Aged; D001792:Blood Platelets / Q000378:metabolism; D001803:Blood Transfusion; D005260:Female; D006801:Humans; D008297:Male; D008722:Methods; D008875:Middle Aged; D010587:Phagocytosis; D017713:Platelet Transfusion; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage* / Q000378:metabolism / Q000627:therapeutic use
D014747:Vinblastine